ARDX Ardelyx Inc

$ARDX Ibsrela - TRx up more than average on a 4 week change but that is off a Holiday week, so on an absolute basis weaker than the previous 3 weeks. The Total patients (4 week sum) 3rd highest for the year. NRx weaker than the last few weeks but slightly above average. RRx about what you would expect with a weaker TRx. So over all, an okay but not good week. Hopefully the positive 4 week changes continue. Other than the Holiday week they have been positive since late July and that is what I like to see, so the since July I would say good progress. They were up and down a lot in June and July. Xphozah- TRx Up on a 4 week change nicely. Back to almost the mid Feb-June range when it was very strong. Nicely above last year. RRx very strong actually above all but 2 this year, one being last week which was the highest of the year. RRx about the recent average. All in all not a bad week, not a great one but showing progress overall.

$ARDX Ibsrela TRx up nicely on the 4 week change. Above the average of the quarter. NRx very strong, not quite as strong as last week but only the 5th time this year above 1600. RRx reasonably strong. Total patients still has the labor day Holiday but still pretty strong. All in all a good week. Xphozah TRx Down on the 4 week change. Still running below Mid-Feb to June but above almost all of the TRx last year. NRx okay, RRx slightly weak. Overall for the quarter the data does not change much from last week.

$ARDX Ibsrela TRx for the quarter very slightly above last quarter. For the week about 6% above the quarterly average and slightly up on a 4 week change basis. NRx great number, nicely above any number this year. RRx reasonable. Xphozah TRx up nicely on a four week change, back to just below the mid-Feb to June range but still nicely above last year. NRx very strong, best of the year. RRx reasonable. Quarterly decently above Q4 and Q1 but quite a bit below Q2.About halfway between Q4 and Q2. All in All a great week for NRx and a good week for TRx. Whether scripts will correlate with revenue depends on how accurate they are compared to actual patients and how different Shipments and GTN are from last quarter.

$ARDX Seeing a lot of posts hoping the IBSRELA payer issues are resolved by Q3. Just wanted to offer a little perspective from someone who’s spent almost 22 years in healthcare reimbursement, albeit in medical devices. Guys…payer friction doesn’t just disappear in two months. Prior authorizations, step therapy and other restrictions are part of healthcare. Some payers will work with you, some won’t, and others may take months or longer. That doesn’t mean the outlook is bad. It means you have to adapt. Improve prescription fulfillment, help physicians navigate requirements, work with individual payers and keep growing demand. For Q3, I don’t need to hear that payer friction is gone. I want to hear that management understands the barriers, has a clear plan and is seeing measurable improvement in getting prescriptions filled” and focused on continued demand growth! I just think investors expecting these issues to magically disappear may be setting themselves up for disappointment…

$ARDX No offense to anyone but all this speculation regarding the importance of the announcement day makes me think back to when people listened to records backwards to hear the hidden message. 😀 IMO the date has zero significance. GLTA.

$ARDX 12$-15$ stock trading at 3,30$ lol Okk .. buying at 25 cents for the dollar. When will it hit 12$-15$ don't know but at some point market will give the true value. Maybe 1 year maybe 2 years. I am ok with that ... I understand longs from 3-4 years maybe tired and regret not selling at 7-9$ range but this prices don't make any sense... I am very positive within a 2 year period this can be at those prices meaning a 300% return. If you can wait it out stay strong IMO.

$ARDX 1) The first poster, FR-PO0316, to be presented at ASN Kidney Week on October 23rd, is highly significant. It states the following: "Of 942,281 pts, 43% had cumulative HP, ~60% of whom were on PBs. Pts on PBs with cumulative HP experienced a ~13%–58% and ~33%–101% higher risk of all-cause mortality (HD and PD, respectively) relative to pts without cumulative HP." What do these figures mean? Out of 942,281 patients, 43% suffered from Cumulative Hyperphosphatemia (HP)—defined as phosphorus levels exceeding 6.5 mg/dL calculated over the first 6 months—and 60% of these were already taking traditional phosphate binders (such as Sevelamer); in other words, 243,000 people were unable to lower their phosphorus levels below 6.5 mg/dL despite taking binders. The study therefore asserts that maintaining these values ​​above 6.5 mg/dL for 6 months increases the risk of hospitalization and death from cardiovascular causes.

$ARDX I don't know about the rest of you longs, but, at these price levels I am taking some solace knowing that at this point the Mike Raab fan club is very, very small - if it even exists at all. Looking forward to better days.

$ARDX just curious - any longs here since 2022? just trying to find some comfort in all of this

$ARDX Yesterday, $IOVA jumped more than 30% after raising 2026 revenue guidance to $410–420M, a $55M increase at the midpoint. Now look at Ardelyx: IBSRELA is guided to $350–370M in 2026 and XPHOZAH to $110–120M, putting combined product revenue around $460–490M. Q2 alone delivered $118.1M in product revenue, +31% YoY, with IBSRELA up 33% and XPHOZAH up 27%. And now August–September prescription trends are improving, especially IBSRELA, suggesting payer friction is becoming more manageable. IOVA just reminded the market what happens when strong execution forces expectations higher. ARDX already has two growing commercial products, improving prescription momentum, and a long-term IBSRELA opportunity still targeting $1B in annual revenue. Sometimes the rerating comes suddenly.

$ARDX Since you are not experienced in the things of the world, all things that have some difficulty seem impossible to you. Trust in time, which usually gives sweet exits to many bitter difficulties. — Miguel de Cervantes Saavedra

$ARDX I just looked (yeah, longingly) at TERN Pharma. TERN was recent Bought out by BP Merck this year (March, 2026) for like $52.95 p share. TERN was like $2.10 per share in just April, 2025. I believe TERN didn’t have any commercial, FDA approved products to offer Merck—unlike ARDX. TERN has a good clinical outlook and a hope and a dream on a novel drug. ARDX has way more to offer a BP. My Dork point for myself—“Dear Dork—Do not give my Dork shares cheap to big money.” I’m adding.

$ARDX I hope a buyout happens here. I honestly don't want to have to listen to Mike Raab's voice anymore - that is kind of where I am at 👍

$ARDX love it I keep buying... This company has good revenues and solid position even with some turbulence now... Will not go BK or anything close to it You are buying a 12$ company TODAY based on revenues at 3,10$ or 25 cents on the dollar... I will sell at over 70 cents on the dollar whenever we get there... And let me tell you next year value is not 12$ is 15$ and 2028 is 18$ and 2029 21$. So I am selling if I see over 10,5$ at some point 2027 Over 12,6$ at some point 2028 Or over 14,7 $ at some point 2029 Call me crazy but I will wait very relaxed. At some point .market will give true or close to true value. IMO. Don't be fooled by all the negativity now...

$ARDX Weekly candle is red for the past 9 weeks & for 13 of the past 14 weeks. Wow. Taking the market at face value, it is telling me, rightly or wrongly, that it believes that the commercial opportunity for tenapanor moving forward is at best, tepid. To the extent that there is virtually no reasonable hope, including exit via a sale to another Pharma company. It can be dangerous to push back against Mr. Market, particularly with an outsized position. Nonetheless, I do not subscribe to that narrative. Ride or die. One day at a time. NIA

$ARDX Pretty much 6months in a row red. Hard to believe it has much more left. Show a profit Raab!

$ARDX Even if the market prices in the stock in advance, the stock's current price is extremely low compared to some companies still in the research and clinical trial stages that generate zero revenues and trade at much higher valuations merely on future expectations—let alone if it were priced compared to companies already in commercial-stage phases.

$ARDX We have a decent chance that the fog around Xphozah will lift in 2027. Then, investors will begin to assign value to it. Together with a proof that Ardelyx can navigate through the payor isssues, will eventually boost valuation here. I‘ll wait for it.

$ARDX Shorts are just messing around because it's easy right now. Next earnings report will give us a new reality check. If numbers and guidance prove them wrong, they’ll have to cover fast and swallow their puts. So far, they haven't seen a reason to do that.

$ARDX I wish we would get a PR saying that Raab asked Morgan Stanley to look for a buyer.